ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Up 5,106.1% in February

ProPhase Labs, Inc. (NASDAQ:PRPH) was the recipient of a significant growth in short interest in February. As of February 15th, there was short interest totalling 4,420,000 shares, a growth of 5,106.1% from the January 31st total of 84,900 shares. Based on an average trading volume of 8,590,000 shares, the short-interest ratio is currently 0.5 days.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of ProPhase Labs in a research note on Tuesday. They set a “sell” rating on the stock.

ProPhase Labs Stock Performance

Shares of PRPH stock opened at $0.46 on Friday. The stock has a market capitalization of $11.09 million, a price-to-earnings ratio of -0.37 and a beta of -0.37. ProPhase Labs has a one year low of $0.22 and a one year high of $7.48. The company’s 50-day simple moving average is $0.52 and its 200-day simple moving average is $1.42. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.33 and a current ratio of 1.47.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. HighTower Advisors LLC raised its position in shares of ProPhase Labs by 18.3% during the 3rd quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock valued at $434,000 after acquiring an additional 27,673 shares in the last quarter. Sheets Smith Wealth Management acquired a new position in ProPhase Labs in the fourth quarter worth $158,000. Geode Capital Management LLC increased its stake in ProPhase Labs by 9.2% during the third quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock valued at $389,000 after purchasing an additional 13,590 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of ProPhase Labs during the fourth quarter worth $40,000. Finally, Renaissance Technologies LLC lifted its position in shares of ProPhase Labs by 33.2% in the 4th quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock worth $217,000 after buying an additional 71,375 shares during the last quarter. Institutional investors own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.